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Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed 
in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT), 
or irinotecan (CPT-11), as single therapies and in combination.
Methods and Materials: LoVo cells were injected subcutaneously into the right hind limb 
(5x106 cells in 100μL phosphate-buffered saline) of athymic NCR NUM mice and tumors were 
grown to a volume of 200–300mm3 before treatment. Vandetanib was administered at 50 mg/kg 
daily orally for 14 days starting on Day 1. RT was given as three fractions (3x3 Gy) on Days 1, 
2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were 
measured on a daily basis and calculated by measuring tumor diameters with digital calipers in 
two orthogonal dimensions.
Results: All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed 
LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11 
and radiation when given in combination with either of these treatments. These treatment
combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration. 
The triple combination of vandetanib, CPT-11, and radiation produced the most marked improve-
ment in response as observed by measurable shrinkage of tumors during the first week of treatment.
Conclusions: The tumor growth delay kinetics observed in this study of the LoVo colorectal 
model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy 
may be beneficial in tumors of this type. ©2009 Elsevier Inc.
Key Words: Vandetanib, Radiotherapy, CPT-11, LoVo colorectal cancer, 
Angiogenesis inhibitor.
Introduction
Colorectal cancer (CRC) remains one of the leading causes of mortality worldwide. In recent years, 
the most widely used chemotherapy for metastatic CRC, fluoropyrimidine (5-fluorouracil [5-FU]) in 
combination with folinic acid, has been combined with newer, highly active cytotoxic agents. Among 
these agents is the DNA topoisomerase I inhibitor, irinotecan (CPT-11),1 a potent DNA-targeting 
drug used in patients with CRC that is refractory to treatment with fluorouracil and leucovorin. 
This cytotoxic agent is, in turn, being combined with new molecular therapies targeting the tumor 
vasculature and key signaling pathways controlling tumor cell proliferation, angiogenesis, and 
survival in CRC. In this regard, the epidermal growth factor receptor (EGFR) plays an important 
role in CRC tumor growth and progression,2 and cetuximab, a monoclonal antibody specific for 
EGFR, has been approved for use in combination with CPT-11 in patients with EGFR-expressing  CRC 
refractory to CPT-11–based chemotherapy.3 In addition, bevacizumab, a monoclonal  antibody 
specific for vascular endothelial growth 
factor (VEGF-A), a key player in tumor 
angiogenesis in CRC as well as other solid 
tumors, has been approved for the treatment 
of metastatic CRC in combination with 
intravenous 5-FU–based chemotherapies.4 
Despite recent improvements in treatment 
for CRC, a need still remains to improve the 
performance of existing treatments and to 
establish the optimum scheduling and dosing 
of combined therapies.
Vandetanib (ZACTIMA) is an oral receptor 
tyrosine kinase inhibitor that, in recombinant 
enzyme assays, demonstrates potent activity 
against vascular endothelial growth factor 
receptor-2 (VEGFR-2) tyrosine kinase (the half 
maximal inhibitory concentration [IC50]=40 
nmol/L) with additional activity against 
EGFR (IC50=500 nmol/L) and the rearranged 
during transfection (RET) tyrosine kinases 
(IC50=130nM) tyrosine kinases.5–8 Vandetanib 
has orphan-drug status in the United States 
and Europe for medullary thyroid cancer 
(in which RET activity is important) and is 
in Phase III development in non–small-cell 
lung cancer and medullary thyroid cancer. 
Phase II studies are ongoing to investigate its 
efficacy in other tumor types, thyroid cancer, 
hepatocellular carcinoma, and glioblastoma.
Vandetanib has been shown to enhance the 
efficacy of radiotherapy in subcutaneous and 
orthotopic tumor xenograft models.9–13 The 
combination of vandetanib, radiation, and 
current chemotherapeutic agents used in CRC 
treatment has not been studied. Preclinical 
demonstration of efficacy of a combination 
protocol with novel agents plus radiation 
is usually considered crucial before clinical 
evaluation. The purpose of the present study was 
to examine the effect of vandetanib on the radi-
ation response of a colorectal tumor model when 
administered in combination with CPT-11. It was 
hypothesized that simultaneous inhibition of 
VEGFR and EGFR by vandetanib in combination 
with the cytotoxic agent CPT-11 would interact 
to enhance radiation response and tumor control 
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in the human LoVo colorectal tumor cell model. The LoVo colorectal model 
expresses activated EGFR14, 15 and is highly vascularized and therefore is an 
appropriate model to test the hypothesis.
Methods and Materials
Animal and tumor model
LoVo cell suspensions (5x106 cells in 100 μL phosphate buffered saline) 
were implanted subcutaneously into the right hind limbs of 6- to 8-
week-old athymic NCR NUM mice (Taconic Farms, Hudson, NY). A
subcutaneous xenograft model was chosen to facilitate radiation dos-
ing and ease of tumor measurements. Tumors were allowed to grow for
approximately 25 days, until reaching an approximate volume of 200–
300mm3 at the start of treatment (Day 1). All animals were randomized 
among treatment groups.
Drug treatment
Vandetanib (AstraZeneca, Macclesfield, UK) was administered by oral 
gavage at 50mg/kg daily for 14 days, starting on Day 1. Vandetanib 
dosing in this study was based on previous pharmacokinetic studies in 
mouse models predicting relevance of this dosing to clinical drug expo-
sure in human patients.16 CPT-11 was given at 15mg/kg intraperitoneally 
on Days 1 and 3.
Radiation treatment
Irradiation was performed on anesthetized mice using X-rays generated 
by a PanTak, 310 kVe X-ray machine, 0.25mm Cu+1mm Al added filtra-
tion, at 125cGy/min. Dosimetry was performed by an in-the-beam ion-
ization chamber calibrated against a primary standard. Corrections were 
made daily for humidity, temperature, and barometric pressure. Mice 
were anesthetized with a combination of ketamine and acepromazine 
at a concentration of 37.5mg/kg and 0.2mg/kg, respectively, to provide 
25–30 min of sedation. Each mouse was confined in a lead casing with 
its tumor-bearing leg extended through an opening on the side to allow 
the tumor to be irradiated locally. Radiation was administered as three 
daily fractions of 3 Gy each on Days 1, 2, and 3. On days when radiation 
was administered with vandetanib or CPT-1, vandetanib and CPT-11 
were given approximately 2h before radiation, with vandetanib preceding 
CPT-11 administration.
Tumor measurement
Tumors were synchronized to be approximately 250 mm3 at the start of 
treatment (Day 1) and were measured four to five times per week, for 
up to 6 weeks of follow-up, or until they reached 2,000 mm3. Tumor 
size was determined by direct measurement with calipers and calculated 
by the formula: (smallest diameter2 x widest diameter)/2. Tumors were 
not allowed to grow beyond 2,000 mm3 in accordance with Institutional
Animal Care and Use Committee regulations.
In vivo tumor necrosis
Tumors were collected from animals on Day 14 after the start of treat-
ment for fixation and staining with hematoxylin and eosin. The area of 
necrosis was evaluated by image analysis and expressed as the percentage 
of the total tumor area.
Statistical analysis
Tumor growth was analyzed via mixed-effects regression, as previously 
described. The method was used because it does not depend on an 
arbitrary end point target tumor size, but uses the repeated tumor size 
measurements obtained over the entire study period, while appropriately 
handling unbalanced data (i.e., different number of measurements for 
different animals) and the correlation of each animal’s measurements 
over time. Mixed-effects regression yields generalizable parameters of 
interest (e.g., average daily tumor growth rate, tumor doubling time), and 
can investigate treatment interactions and nonlinear patterns of tumor 
growth. The base-10 logarithm of tumor volume was modeled as a func-
tion of time and treatment. Linear or quadratic growth curves over time 
were fitted to the log-transformed data, depending on growth patterns 
in each treatment group. All statistical analyses were conducted in SAS 
9.2 (SAS Institute Inc., Cary, NC, 1999–2001).
Results
The experiment involved three different treatments (vandetanib, CPT-11, 
and radiotherapy), as described above and summarized in Fig. 1. Data 
were collected from a total of 104 animals in eight experimental groups 
(11–16 animals per group) and are summarized in Fig. 2. Starting 
tumor sizes were comparable across groups, with geometric means
ranging from 230 to 257mm3 (p = 0.771). All treatments were well
tolerated in the animals with no observable loss of body weight.
The three single-treatment groups (CPT-11, radiation, or vandetanib), 
as well as the combination of CPT-11 with radiation (Fig. 2) were 
fitted to log-transformed curves, whereas the three remaining groups 
that received combination treatments involving vandetanib showed 
a significantly nonlinear tumor growth and were fitted to quadratic curves.
Figure 3 shows the measured geometric mean tumor size graphically over 
time. Table 1 shows the corresponding calculated tumor growth parameters 
(daily tumor growth rate and tumor doubling time). Table 2 shows p values 
for group comparisons at 7, 14, and 21 days after start of treatment.
CPT-11
RT
Vandetanib
CPT-11
+ RT
CPT-11
+ vandetanib
RT
+ vandetanib
CPT-11
+ RT
+ vandetanib
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Tumor volume – 250 mm3
Control (untreated) group not shown
Day
Figure 1. Summary of treatment groups. LoVo cells were implanted 
subcutaneously into the right hind limbs of athymic NCR NUM 
male mice. Mice were randomized into eight experimental groups 
(11–16 animals per group). Vandetanib was administered at 50 mg/
kg daily orally for 14 days, starting on Day 1. CPT-11 was given at 
15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given 
as three fractions (3x3 Gy) on Days 1, 2, and 3.
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The control group had an estimated average daily tumor growth rate 
of 9.9%, corresponding to an average tumor doubling time of about 
7 days (Table 1). All three single treatments resulted in a significant 
inhibition of tumor growth, compared with the control group (average 
daily tumor growth rates: CPT-11: 7.1%, p = 0.015; radiation: 5.6%, 
p = 0.001; vandetanib: 5.0%, p = 0.001). Vandetanib inhibited tumor 
growth significantly more than CPT-11 (p = 0.043), but not radiation 
(p = 0.514); radiation and CPT-11 were not significantly different 
(p = 0.139). The combination of CPT-11 with radiation produced a 
daily tumor growth rate of 5.1%, which was significantly lower than 
CPT-11 alone (p = 0.015) but comparable to radiation alone (p = 0.560). 
There was no significant (additive) interaction between CPT-11 and 
radiation (p = 0.105).
The remaining three groups that received treatment combinations 
involving vandetanib (with either CPT-11 or radiation, or with both 
CPT-11 and radiation), showed significant treatment interactions 
(p = 0.001 for the interaction between vandetanib and CPT-11 and 
between vandetanib and radiation) and nonlinear tumor growth patterns. 
Compared with single-treatment groups, growth was significantly 
delayed (and, in the triple-treatment combination, tumor volume 
actually decreased) early on, but progressively accelerated later, although 
it never exceeded that of the untreated controls (Fig. 3). Because of the 
nonlinearity of tumor growth in these groups, tumor growth parameters 
are not constant over time and comparisons depend on the time point 
referenced. Table 2 shows p values for Days 7, 14, and 21.
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Figure 2. Tumor growth curves in LoVo xenografts treated with vandetanib, irinotecan (CPT-11), and/or radiation. Individual mouse data are 
shown for eight treatment groups (11–16 animals per group), along with fitted group curves. Vandetanib was administered at 50 mg/kg daily 
orally for 14 days, starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given as three fractions 
(3x3 Gy) on Days 1, 2, and 3.
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During the first week of treatment, animals receiving the combination 
of vandetanib with CPT-11 had average daily tumor growth rate of 
less than 3.5%, significantly lower than CPT-11 alone and marginally 
so compared with vandetanib alone (p = 0.001 and 0.058, respectively, 
after 7 days). By the end of the 2-week vandetanib treatment, the 
tumor growth rate in the combination group (4.6%) was still significantly 
lower than for CPT-11 alone (p = 0.015) but comparable to that for
vandetanib alone (p = 0.682). By the third and fourth weeks, tumor 
growth had reached levels similar to those seen in the single-treatment 
groups (Fig. 3, Table 1).
The combination of vandetanib with radiation resulted in a similar 
pattern of nonlinear tumor growth inhibition. After the first 7 days, 
the average daily tumor growth rate of 2.1% was significantly lower 
than for either radiation alone or vandetanib alone (p = 0.005 and 
0.019, respectively). After 14 days, the tumor growth rate in the
combination group had accelerated to 3.4% and was only marginally 
lower than for radiation alone and comparable to that for vandetanib 
alone (p=0.080 and 0.212, respectively). By the third and fourth 
weeks, tumor growth had become similar to that seen in the single-
treatment groups (Fig. 3, Table 1).
Despite delaying tumor growth in the initial weeks, the treatment 
combinations induced only modest levels of tumor necrosis (10–20%), 
with no significant differences between treatment groups (Fig. 4).
The pattern of tumor growth in the group that received the triple-
treatment combination reflected both the interaction between 
vandetanib and CPT-11 and that between vandetanib and radiation
(as mentioned previously). Thus, during the first week, instead of 
the delayed tumor growth seen in the two-treatment combinations, 
tumor volume in the triple-treatment combination actually decreased
(p = 0.001 vs. vandetanib plus CPT-11, and 0.052 vs. vandetanib plus 
radiation). After that time, similar to the two-treatment combinations 
that involved vandetanib, tumor growth started accelerating. By the end 
of the third week, tumor growth in the triple-treatment combination 
group was similar to that in the two-treatment combination groups 
involving vandetanib, and by the fourth week, it was similar to that in the 
single-treatment groups.
Discussion
Relatively little is known about the antitumor effects of combining
cytotoxic drugs, radiotherapy, and novel targeted therapies that specifically 
interfere with signaling pathways controlling cancer proliferation, angio-
genesis, and survival. In the present study, vandetanib, a potent inhibitor 
of both VEGFR and EGFR signaling, was combined with CPT-11 or radia-
tion, to determine if greater anti-colorectal tumor activity can be obtained. 
This study demonstrated that all three single treatments (vandetanib, 
CPT-11, and radiation) significantly slowed LoVo colorectal tumor 
growth. Previous studies with single-agent vandetanib demonstrated 
that chronic oral administration reduced tumor vascularity and tumor 
growth in a variety of xenograft models, including CRC.7, 17 In the clinic, 
the safety and tolerability of vandetanib has been demonstrated in 
patients with advanced colorectal cancer as well as other solid tumors.18 
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Figure 3. Estimated geometric mean tumor volume over time in 
LoVo xenografts treated with vandetanib, CPT-11, and/or radiation. 
Vandetanib was administered at 50 mg/kg daily orally for 14 days, 
starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally 
on Days 1 and 3. Radiation was given as three fractions (3x3 Gy) 
on Days 1, 2, and 3.
Table 1. Estimates of the average daily tumor growth rate and average tumor doubling time, by treatment group
Time (days)
  1 7 14 21 28 35 __________ __________ __________ __________ __________ __________
 %Δ(T2x) %Δ(T2x) %Δ(T2x) %Δ(T2x) %Δ(T2x) %Δ(T2x)
CTR       9.9   (7.4)   
CPT-11       7.1 (10.2) 
RT      5.6 (12.7) 
VAN      5.0 (14.3)  
CPT-11 + RT      5.1 (13.9) 
VAN + CPT-11    1.9 (37.1)  3.2 (22.2)  4.6 (15.5)  6.0 (11.9)  7.4 (9.7)  8.9 (8.2) 
VAN + RT 0.9 (75.4)  2.1 (33.4)  3.4 (20.9) 4.7 (15.2)  6.0 (11.9)  7.3 (9.8)
VAN + CPT-11 + RT   -2.1 N/A  0.0 N/A  2.4 (28.7)  4.9 (14.5)  7.4 (9.7)  9.9 (7.3)
%Δ: estimated average daily rate of increase/decrease of tumor volume (%).
T2x: estimated average doubling time of tumor volume (in days).
N/A: not applicable (tumor shrinks or is stable).
CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth, so their parameters were constant over time. The remaining
groups did not have log-linear tumor growth, so their parameters were changing over time.
†
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Vandetanib induced manageable normal tissue toxicities related to 
inhibition of EGFR and VEGFR signaling such as diarrhea, rash, and 
hypertension.19, 20 The effect of combining radiation and vandetanib on 
normal tissue is currently unknown, however it has been shown in both 
preclinical and clinical trials that use of VEGF inhibitors with radiation 
may result in higher rates of normal tissue toxicity such as induction 
of thrombosis, hemorrhage, and bowel toxicities.21–23 In contrast, it was 
postulated that combination of radiotherapy with inhibitors of angio-
genesis may actually decrease these risks because radiotherapy has been 
used to prevent hemorrhage.24 Overall, the investigation of agents such 
as vandetanib in combination with radiation in normal tissue is lacking, 
and thus will be a major focus in the future.
As previously discussed, single-agent vandetanib has dual tyrosine 
kinase inhibitory activity against VEGFR-2 and EGFR, which allows 
it to target two key pathways responsible for tumor growth (i.e., tumor 
angiogenic signaling, tumor cell proliferation). It has been speculated 
that dual suppression may be critical for sustained suppression of tumor 
growth, especially because the EGFR and VEGFR pathways are linked 
and exhibit cross-talk.25 In addition, vandetanib can also enhance the 
antiproliferative activity of selective EGFR inhibitors such as cetuximab, 
thereby potentiating suppression of EGFR signaling.17
The present study confirmed that vandetanib, chronically administered 
over 2 weeks, slowed tumor growth in a colorectal tumor model, and, 
under the dosing conditions of this study, slowed tumor growth to 
a greater extent than CPT-11 alone and to a similar level to radiation 
alone. Moreover, vandetanib significantly increased the antitumor effects 
of CPT-11 and radiation, when given in combination with either of these 
treatments. In particular, these treatment combinations resulted in a slow 
tumor growth rate during the 2 weeks of vandetanib administration. These 
results confirm an earlier study by Troiani et al.,26 in which vandetanib 
Radiotherapy
Table 2. P-values for comparisons of treatment groups, on days 7, 14, and 21, after the start of treatment
 Day 7  Day 14  Day 21
CTR 
CPT-11   0.015 vs. CTR; 0.139 vs. RT; 0.043 vs. VAN
RT  0.001 vs. CTR; 0.139 vs. CPT-11; 0.514 vs. VAN 
VAN  0.001 vs. CTR; 0.043 vs. CPT-11; 0.514 vs. RT 
CPT-11 + RT   0.001 vs. CPT-11; 0.560 vs. RT
VAN + CPT-11  0.001 vs. CPT-11; 0.058 vs. VAN  0.015 vs. CPT-11; 0.682 vs. VAN  0.346 vs. CPT-11; 0.395 vs. VAN
VAN + RT 0.005 vs. RT; 0.019 vs. VAN  0.080 vs. RT; 0.212 vs. VAN  0.496 vs. RT; 0.830 vs. VAN
VAN + CPT-11 + RT  0.001 vs. CPT-11; 0.001 vs. RT; 0.001 vs. CPT-11; 0.001 vs. RT;  0.011 vs. CPT-11; 0.366 vs. RT;
 0.001 vs. VAN 0.007 vs. VAN 0.917 vs. VAN
 0.001 vs. CPT-11+RT; 0.001 vs. 0.001 vs. CPT-11+RT; 0.017 vs. 0.766 vs. CPT-11+RT; 0.294 vs.
 VAN+CPT-11; 0.052 vs. VAN+CPT-11; 0.407 vs. VAN+CPT-11; 0.868 vs.
 VAN+RT VAN+RT VAN+RT
CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth and therefore comparisons do not depend on time.
The remaining groups did not have log-linear tumor growth and therefore comparisons that involve them depend on time.
Figure 4. Hematoxylin and eosin stained 
sections of LoVo colorectal xenografts. All 
tumors were collected from animals on Day 
14 after the start of treatment. Areas of 
necrosis are denoted by nec. Magnification 
20x. (a) Control (untreated) tumor, showing 
2% necrosis. (b) Tumor from animal after 
administration of last dose of vandetanib, 
showing 15% necrosis. (c) Tumor from 
animal after administration of CPT-11 and 
RT, showing 20% necrosis. (d) Tumor from 
animal after administration of vandetanib and 
CPT-11, showing 10% necrosis.
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(25mg/kg/day) administered in combination with CPT-11 exhibited 
high antitumor activity in HT29-tumor–bearing nude mice. Troiani et al. 
showed a correlation between this dosing schedule and enhanced EGFR 
and VEGFR signal inhibition.
In the present study, the triple combination of vandetanib, CPT-11, and 
radiation produced the most marked improvement in response in the 
LoVo- tumor–bearing mice. The triple treatment produced a measurable 
shrinkage of tumors during the first week of treatment. The combination of
vandetanib, chemotherapy (gemcitabine), and radiation has also been 
previously shown to significantly inhibit tumor progression in a pancreatic 
tumor model.27 Importantly, the present study also investigated the 
kinetics of tumor growth, both during and after a course of treatment. It was 
demonstrated that the addition of vandetanib significantly  enhanced 
the initial antitumor effect of chemo-radiation. However, when vandetanib 
treatment ended, tumor growth returned to near control (untreated) 
levels. Therefore, these data support the rationale of adding an antivascular 
agent to cytotoxic therapies and provide valuable information for the 
design of therapeutic protocols.
The precise mechanisms leading to initial tumor regression with the 
combined therapies in this study are not known. Analysis of interactions 
between cytotoxic agents and vandetanib is complex, given that both 
the tumor cells and the tumor microenvironment are affected. In this 
connection, radiation can kill not only tumor cells but also endothelial 
cells of the tumor vasculature, thereby affecting the radiosensitivity of 
the tumor (28, 29). In addition, cytotoxic agents have mechanisms of cell 
killing that are different from the targeted agent. Both radiation and CPT-11 
kill cells through DNA damage. Both chemotherapy and radiation can 
also alter cellular signaling pathways by inducing EGFR phosphorylation 
and through the growth factor signaling pathway, contribute to tumor 
cell proliferation and survival.30–32 Preclinical studies have also shown that 
cytotoxic therapy alone, such as radiation, can result in intensification 
of angiogenic processes.33 After cytotoxic treatment, upregulation of 
vascular growth factors and their receptors occurs, which contributes 
to tumor recurrence and progression.34 Direct upregulation of VEGF 
after irradiation of various cancer cell lines has been reported.35 Radia-
tion also induces transient tumor hypoxia which results in upregulation 
of hypoxia inducible factor-1 (HIF-1) which can stimulate VEGF and 
VEGFR-2 expression. Therefore, simultaneous inhibition of both VEGFR 
and EGFR signaling through chronic administration of vandetanib in 
combination with cytotoxic therapy is expected to suppress the upsurge 
in pro-proliferative and angiogenic signaling resulting from CPT-11 and 
radiation-induced EGFR and VEGF. This suppression will thereby lead 
to inhibition of vascular protective mechanisms and growth factor
mechanisms contributing to tumor regrowth.
The increased tumor growth that was seen in this study after discon-
tinuation of vandetanib suggests that inhibition of angiogenic and pro-
proliferative signaling is readily reversed. The current observations are in 
agreement with a number of both preclinical and clinical studies showing 
that tumors can adapt to anti-angiogenic treatment by undergoing 
‘‘evasive resistance’’ to angiogenesis inhibitors.36 Mechanisms of resistance 
include upregulation of alternative proangiogenic signaling pathways as 
well as recruitment of bone marrow–derived proangiogenic cells.37, 38
In addition, administration of vandetanib itself has been observed to 
increase VEGF production in certain cancer cell lines as well as in tumor 
xenografts,39, 40 thereby suggesting an additional contributing mechanism 
to tumor relapse. More studies will be needed to determine whether addi-
tional angiogenic pathways may be induced by triple modality treatment.
Conclusions
The results of this study provide a scientific rationale for testing the 
combination of vandetanib, CPT-11, and radiation in patients with 
CRC. Although the best schedule and sequencing for this triple modality 
treatment has yet to be determined, the tumor growth delay kinetics 
observed in this study suggest that improvement in colorectal 
tumor response can be obtained by concurrent and sustained post-
sequencing of vandetanib with cytotoxic therapy, keeping in mind 
that prolonged chronic administration of the receptor tyrosine kinase 
inhibitors may lead to the development of resistance and the requirement 
for additional therapeutic agents as seen with other targeted agents, 
such as imatinib and gefitinib.41, 42
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